Top

Published in:

01-12-2012 | Neurology and Preclinical Neurological Studies - Short communication

Does structural neuroimaging reveal a disturbance of iron metabolism in Parkinson’s disease? Implications from MRI and TCS studies

Authors: Adriane Gröger, Daniela Berg

Published in: Journal of Neural Transmission | Issue 12/2012

Abstract

A central role of iron in the pathogenesis of Parkinson’s disease (PD) has been discussed for many years. Numerous studies using magnetic resonance imaging and transcranial sonography have been performed to detect alterations in tissue iron content of the substantia nigra. This manuscript reviews the findings of this still controversial issue and indicates that specific abnormalities that are suggested to be related to a disturbance of iron homeostasis may play an early role in the pathogenesis of PD.

Antonini A, Leenders KL, Meier D, Oertel WH, Boesiger P, Anliker M (1993) T2 relaxation time in patients with Parkinson’s disease. Neurology 43:697–700PubMedCrossRef

Atasoy HT, Nuyan O, Tunc T, Yorubulut M, Unal AE, Inan LE (2004) T2-weighted MRI in Parkinson’s disease; substantia nigra pars compacta hypointensity correlates with the clinical scores. Neurol India 52:332–337PubMed

Bartzokis G, Cummings JL, Markham CH, Marmarelis PZ, Treciokas LJ, Tishler TA, Marder SR, Mintz J (1999) MRI evaluation of brain iron in earlier- and later-onset Parkinson’s disease and normal subjects. Magn Reson Imaging 17:213–222PubMedCrossRef

Baudrexel S, Nürnberger L, Rüb U, Seifried C, Klein JC, Deller T, Steinmetz H, Deichmann R, Hilker R (2010) Quantitative mapping of T1 and T2* discloses nigral and brainstem pathology in early Parkinson’s disease. Neuroimage 51:512–520PubMedCrossRef

Behnke S, Schroeder U, Dillmann U, Buchholz HG, Schreckenberger M, Fuss G, Reith W, Berg D, Krick CM (2009) Hyperechogenicity of the substantia nigra in healthy controls is related to MRI changes and to neuronal loss as determined by F-Dopa PET. Neuroimage 47:1237–1243PubMedCrossRef

Berg D (2007) Disturbance of iron metabolism as a contributing factor to SN hyperechogenicity in Parkinson’s disease: implications for idiopathic and monogenetic forms. Neurochem Res 32:1646–1654PubMedCrossRef

Berg D (2011) Substantia nigra hyperechogenicity is a risk marker of Parkinson’s disease: yes. J Neural Transm 118:613–619PubMedCrossRef

Berg D, Becker G, Zeiler B, Tucha O, Hofmann E, Preier M, Benz P, Jost W, Reiners K, Lange KW (1999a) Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 53:1026–1031PubMedCrossRef

Berg D, Grote C, Rausch WD, Mäurer M, Wesemann W, Riederer P, Becker G (1999b) Iron accumulation of the substantia nigra in rats visualized by ultrasound. Ultrasound Med Biol 25:901–904PubMedCrossRef

Berg D, Roggendorf W, Schröder U, Klein R, Tatschner T, Benz P, Tucha O, Preier M, Lange KW, Reiners K, Gerlach M, Becker G (2002) Echogenicity of the substantia nigra—association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 59:999–1005PubMedCrossRef

Berg D, Merz B, Reiners K, Naumann M, Becker G (2005) A five year follow-up study of hyperechogenicity of the substantia nigra in Parkinson′s disease. Mov Disord 20:383–385PubMedCrossRef

Berg D, Godau J, Walter U (2008) Transcranial sonography in movement disorders. Lancet Neurol 7:1044–1055PubMedCrossRef

Berg D, Seppi K, Behnke S, Liepelt I, Schweitzer K, Stockner H, Wollenweber F, Gaenslen A, Mahlknecht P, Spiegel J, Godau J, Huber H, Srulijes K, Kiechl S, Bentele M, Gasperi A, Schubert T, Hiry T, Probst M, Schneider V, Klenk J, Sawires M, Willeit J, Maetzler W, Fassbender K, Gasser T, Poewe W (2011) Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons. Arch Neurol 68:932–937PubMedCrossRef

Braffman BH, Grossman RI, Goldberg HI, Stern MB, Hurtig HI, Hackney DB, Bilaniuk LT, Zimmerman RA (1989) MR imaging of Parkinson disease with spin-echo and gradient-echo sequences. AJR Am J Roentgenol 152:159–165PubMed

Brass SD, Chen NK, Mulkern RV, Bakshi R (2006) Magnetic resonance imaging of iron deposition in neurological disorders. Top Magn Reson Imaging 17:31–40PubMedCrossRef

Connor JR, Boeshore KL, Benkovic SA, Menzies SL (1994) Isoforms of ferritin have a specific cellular distribution in the brain. J Neurosci Res 37:461–465PubMedCrossRef

De Rijk MC, Tzourio C, Breteler MMB, Dartigues JF, Amaducci L, Lopez-Pousa S, Manubens-Bertran JM, Alperovitch A, Rocca WA (1997) Prevalence of parkinsonism and Parkinson’s disease in Europe: the EUROPARKINSON collaborative study. J Neurol Neurosurg Psychiatry 62:10–15PubMedCrossRef

Dexter DT, Sian J, Jenner P, Marsden CD (1993) Implications of alterations in trace element levels in brain in Parkinson’s disease and other neurological disorders affecting the basal ganglia. Adv Neurol 60:273–281PubMed

Du G, Lewis MM, Styner M, Shaffer ML, Sen S, Yang QX, Huang X (2011) Combined R2* and diffusion tensor imaging changes in the substantia nigra in Parkinson’s disease. Mov Disord 26:1627–1632PubMedCrossRef

Gaenslen A, Unmuth B, Godau J, Liepelt I, Di Santo A, Schweitzer KJ, Gasser T, Machulla HJ, Reimold M, Marek K, Berg D (2008) The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson’s disease: a prospective blinded study. Lancet Neurol 7:417–424PubMedCrossRef

Gerlach M, Ben-Shachar D, Riederer P, Youdim MB (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases. J Neurochem 63:793–807PubMedCrossRef

Gorell JM, Ordidge RJ, Brown GG, Deniau JC, Buderer NM, Helpern JA (1995) Increased iron-related MRI contrast in the substantia nigra in Parkinson’s disease. Neurology 45:1138–1143PubMedCrossRef

Graham JM, Paley MN, Grünewald RA, Hoggard N, Griffiths PD (2000) Brain iron deposition in Parkinson’s disease imaged using the PRIME magnetic resonance sequence. Brain 123:2423–2431PubMedCrossRef

Gupta D, Saini J, Kesavadas C, Sarma PS, Kishore A (2010) Utility of susceptibility-weighted MRI in differentiating Parkinson’s disease and atypical parkinsonism. Neuroradiology 52:1087–1094PubMedCrossRef

Haacke EM, Cheng NY, House MJ, Liu Q, Neelavalli J, Ogg RJ, Khan A, Ayaz M, Kirsch W, Obenaus A (2005) Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging 23:1–25PubMedCrossRef

Haacke EM, Mittal S, Wu Z, Neelavalli J, Cheng YC (2009) Susceptibility-weighted imaging: technical aspects and clinical applications, part 1. AJNR Am J Neuroradiol 30:19–30PubMedCrossRef

Huang XM, Sun B, Xue YJ, Duan Q (2010) Susceptibility-weighted imaging in detecting brain iron accumulation of Parkinson’s disease. Zhonghua Yi Xue Za Zhi 90:3054–3058PubMed

Iranzo A, Lomeña F, Stockner H, Valldeoriola F, Vilaseca I, Salamero M, Molinuevo JL, Serradell M, Duch J, Pavía J, Gallego J, Seppi K, Högl B, Tolosa E, Poewe W, Santamaria J; Sleep Innsbruck Barcelona (SINBAR) group (2010) Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol 9:1070–1077

Jin L, Wang J, Zhao L, Jin H, Fei G, Zhang Y, Zeng M, Zhong C (2011) Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson’s disease. Brain 134:50–58PubMedCrossRef

Kosta P, Argyropoulou MI, Markoula S, Konitsiotis S (2006) MRI evaluation of the basal ganglia size and iron content in patients with Parkinson’s disease. J Neurol 253:26–32PubMedCrossRef

Lotfipour AK, Wharton S, Schwarz ST, Gontu V, Schäfer A, Peters AM, Bowtell RW, Auer DP, Gowland PA, Bajaj NP (2012) High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson’s disease. J Magn Reson Imaging 35:48–55PubMedCrossRef

Martin WR, Wieler M, Gee M (2008) Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 70:1411–1417PubMedCrossRef

Michaeli S, Oz G, Sorce DJ, Garwood M, Ugurbil K, Majestic S, Tuite P (2007) Assessment of brain iron and neuronal integrity in patients with Parkinson’s disease using novel MRI contrasts. Mov Disord 22:334–340PubMedCrossRef

Mondino F, Filippi P, Magliola U, Duca S (2002) Magnetic resonance relaxometry in Parkinson’s disease. Neurol Sci 23:S87–S88PubMedCrossRef

Nestrasil I, Michaeli S, Liimatainen T, Rydeen CE, Kotz CM, Nixon JP, Hanson T, Tuite PJ (2010) T1rho and T2rho MRI in the evaluation of Parkinson’s disease. J Neurol 257:964–968PubMedCrossRef

Ordidge RJ, Gorell JM, Deniau JC, Knight RA, Helpern JA (1994) Assessment of relative brain iron concentrations using T2-weighted and T2*-weighted MRI at 3 Tesla. Magn Reson Med 32:335–341PubMedCrossRef

Péran P, Cherubini A, Assogna F, Piras F, Quattrocchi C, Peppe A, Celsis P, Rascol O, Démonet JF, Stefani A, Pierantozzi M, Pontieri FE, Caltagirone C, Spalletta G, Sabatini U (2010) Magnetic resonance imaging markers of Parkinson’s disease nigrostriatal signature. Brain 133:3423–3433PubMedCrossRef

Riederer P, Rausch WD, Schmidt B, Kruzik P, Konradi C, Sofic E, Danielczyk W, Fischer M, Ogris E (1988) Biochemical fundamentals of Parkinson’s disease Mt. Sinai J Med 55:21–28

Ruprecht-Dörfler P, Berg D, Tucha O, Benz P, Meier-Meitinger M, Alders GL, Lange KW, Becker G (2003) Echogenicity of the substantia nigra in relatives of patients with sporadic Parkinson’s disease. NeuroImage 18:416–422PubMedCrossRef

Rutledge JN, Schallert T, Hall S (1993) Magnetic resonance imaging in parkinsonisms. Adv Neurol 60:529–534PubMed

Ryvlin P, Broussolle E, Piollet H, Viallet F, Khalfallah Y, Chazot G (1995) Magnetic resonance imaging evidence of decreased putamenal iron content in idiopathic Parkinson’s disease. Arch Neurol 52:583–588PubMedCrossRef

Savoiardo M, Girotti F, Strada L, Ciceri E (1994) Magnetic resonance imaging in progressive supranuclear palsy and other parkinsonian disorders. J Neural Transm Suppl 42:93–110PubMedCrossRef

Schuff N (2009) Potential role of high-field MRI for studies in Parkinson’s disease. Mov Disord 24:S684–S690PubMedCrossRef

Sofic E, Riederer P, Heinsen H, Beckmann H, Reynolds GP, Hebenstreit G, Youdim MB (1988) Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 74:199–205PubMedCrossRef

Solomon I (1955) Relaxation processes in a system of two spins. Phys Rev 99:559–565CrossRef

Vymazal J, Brooks RA, Baumgarner C, Tran V, Katz D, Bulte JW, Bauminger R, Di Chiro G (1996) The relation between brain iron and NMR relaxation times: an in vitro study. Magn Reson Med 35:56–61PubMedCrossRef

Vymazal J, Righini A, Brooks RA, Canesi M, Mariani C, Leonardi M, Pezzoli G (1999) T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content. Radiology 211:489–495PubMed

Wallis LI, Paley MN, Graham JM, Grünewald RA, Wignall EL, Joy HM, Griffiths PD (2008) MRI assessment of basal ganglia iron deposition in Parkinson’s disease. J Magn Reson Imaging 28:1061–1067PubMedCrossRef

Wang Y, Butros SR, Shuai X, Dai Y, Chen C, Liu M, Haacke EM, Hu J, Xu H (2012) Different iron-deposition patterns of multiple system atrophy with predominant parkinsonism and idiopathetic Parkinson diseases demonstrated by phase-corrected susceptibility-weighted imaging. AJNR Am J Neuroradiol 33:266–273PubMedCrossRef

Zecca L, Berg D, Arzberger T, Ruprecht P, Rausch WD, Musico M, Tampellini T, Riederer P, Gerlach M, Becker G (2005) In vivo detection of iron and neuromelanin by transcranial sonography a new approach for early detection of substantia nigra damage. Mov Disord 20:1278–1285PubMedCrossRef

Zhang W, Sun SG, Jiang YH, Qiao X, Sun X, Wu Y (2009) Determination of brain iron content in patients with Parkinson’s disease using magnetic susceptibility imaging. Neurosci Bull 25:353–360PubMedCrossRef

Zhang J, Zhang Y, Wang J, Cai P, Luo C, Qian Z, Dai Y, Feng H (2010) Characterizing iron deposition in Parkinson’s disease using susceptibility-weighted imaging: an in vivo MR study. Brain Res 1330:124–130PubMedCrossRef

Title: Does structural neuroimaging reveal a disturbance of iron metabolism in Parkinson’s disease? Implications from MRI and TCS studies
Authors: Adriane Gröger
Daniela Berg
Publication date: 01-12-2012
Publisher: Springer Vienna
Published in: Journal of Neural Transmission / Issue 12/2012
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-012-0873-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Does structural neuroimaging reveal a disturbance of iron metabolism in Parkinson’s disease? Implications from MRI and TCS studies

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2012

The history of the research of iron in parkinsonian substantia nigra

The effects of prolonged cathodal direct current stimulation on the excitatory and inhibitory circuits of the ipsilateral and contralateral motor cortex

Swainsonine as a lysosomal toxin affects dopaminergic neurons

Nigral Tau pathology and striatal amyloid-β deposition does not correlate with striatal dopamine deficit in Alzheimer’s disease

Considerations for measuring iron in post-mortem tissue of Parkinson’s disease patients

Positive argument for debate in J Neural Transmission: Alzheimer’s disease: are we intervening too late? Yes, by years if not decades